USPTO serial 87710789
C COMPREHENSIVE CELL SOLUTIONS
Reviewed by CopyMark Law Group
Reg. 5573697Status 710
- Filing date
- Status date
- Registration date
- Oct 2, 2018
- Examiner
- MICKLEBURGH, LINDA BOHANNON
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with C COMPREHENSIVE CELL SOLUTIONS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
CYNTHIA JOHNSON WALDEN
CYNTHIA JOHNSON WALDEN FISH & RICHARDSON P.C.P.O. Box 1022Minneapolis, MN 55440-1022United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Products to support and manage transfusion medicine, regenerative medicine and cellular-therapy related research and clinical programs from discovery through development and to the clinic, namely, blood plasma, blood for medical purposes, blood products for medical and clinical trial use, antibody positive plasma, phenotyped red cell units, monoclonal antibodies to RBC antigens, cord blood; mononuclear cells, progenitor cells, antibody preparations for use in medical clinical trials, research and medical purposes | SECTION 8 - CANCELLED | Jan 23, 2017 |
| 035 | Services to support and manage transfusion medicine, regenerative medicine and cellular-therapy related research and clinical programs from discovery through development and to the clinic, namely, providing independent review of clinical trials for business purposes | SECTION 8 - CANCELLED | Oct 1, 2016 |
| 039 | Services to support and manage transfusion medicine, regenerative medicine and cellular-therapy related research and clinical programs from discovery through development and to the clinic, namely, storage of blood and stem cells | SECTION 8 - CANCELLED | Nov 14, 2016 |
| 040 | Services to support and manage transfusion medicine, regenerative medicine and cellular-therapy related research and clinical programs from discovery through development and to the clinic, namely, cryopreservation of human cells | SECTION 8 - CANCELLED | Nov 14, 2016 |
| 042 | Services to support and manage transfusion medicine, regenerative medicine and cellular-therapy related research and clinical programs from discovery through development and to the clinic, namely, medical laboratory, pharmaceutical research services and pharmaceutical clinical trials for others | SECTION 8 - CANCELLED | Oct 31, 2016 |
| 044 | Services to support and manage transfusion medicine, regenerative medicine and cellular-therapy related research and clinical programs from discovery through development and to the clinic, namely, tissue bank services; cell processing services for use by others; stem cell storage; collection and preservation of human blood, apheresis, red blood cells, plasma and bone marrow | SECTION 8 - CANCELLED | Nov 14, 2016 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by New York Blood Center, Inc.
- Other trademarks owned by New York Blood Center, Inc.
- Other trademarks owned by New York Blood Center, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 039
- Other trademarks in Class 040
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named C COMPREHENSIVE CELL SOLUTIONS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 18, 2025 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| Dec 6, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Dec 6, 2024 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 6, 2024 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Dec 6, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Dec 6, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Oct 2, 2023 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Oct 2, 2018 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 17, 2018 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jul 17, 2018 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 27, 2018 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 4, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 29, 2018 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 29, 2018 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 29, 2018 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 20, 2018 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Mar 20, 2018 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Mar 20, 2018 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Mar 15, 2018 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| Mar 15, 2018 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 13, 2018 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 19, 2017 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Dec 17, 2017 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 9, 2017 | NWAP | NEW APPLICATION ENTERED | — |